NYSE$NUVB
Nuvation Bio Inc · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
Nuvation Bio reported financial results for the first quarter ended March 31, 2021, and provided a business update.
Nuvation Bio reported a net loss of $20.4 million, or $(0.12) per share, and had cash, cash equivalents, and marketable securities of $824.7 million as of March 31, 2021.
- Ongoing enrollment in Phase 1/2 study of NUV-422 in high-grade gliomas.
- Strong balance sheet with cash, cash equivalents and marketable securities of $824.7 million as of March 31, 2021.
- Company remains on track to submit five additional Investigational New Drug (IND) applications by 2026.
- Expect top-line data from the Phase 1 portion of NUV-422 study in 2022.
Headline financials
Revenue & EPS history
Nuvation Bio · Revenue · Quarterly
$0
Forward guidance
The company anticipates therapeutic benefits from its product candidates, expects future IND filings, and looks forward to clinical trial data, while acknowledging the impact of the restatement of Panacea's 2020 financial statements.
Tailwinds
- Potential therapeutic benefit of Nuvation Bio’s product candidates.
- Expected future IND filings.
- Expected timing of clinical trial data.
- Advancing pipeline of therapies for difficult-to-treat cancers.
- Sufficient resources to execute on clinical development plan.
Headwinds
- Restatement of Panacea’s 2020 financial statements.
- Risks and uncertainties discussed in the Quarterly Report on Form 10-Q.
- Potential for actual results to differ materially from forward-looking statements.
- Unforeseen risks that could cause actual results to differ.
- Assessments may change due to subsequent events and developments.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2021
+1.1%
Avg return
Earnings day
+2.7%
Avg return
5 days after
+9.3%
Avg return
30 days after
60%
12 / 20 earnings
Positive
+16.4%
Q3 2023
Best reaction
-25.2%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.0% | +6.7% | +4.9% | |
| Q4 2025 | -25.2% | -21.4% | -24.5% | |
| Q3 2025 | -6.2% | -8.5% | +60.7% | |
| Q1 2025 | +3.5% | +7.4% | +21.6% | |
| Q4 2024 | +1.0% | +0.0% | +0.5% | |
| Q3 2024 | +12.9% | +29.7% | +22.8% | |
| Q2 2024 | -11.3% | -15.8% | -10.4% | |
| Q1 2024 | -2.1% | -1.5% | -11.3% | |
| Q4 2023 | +13.2% | +10.7% | +84.8% | |
| Q3 2023 | +16.4% | +15.5% | +14.7% | |
| Q2 2023 | +0.5% | +12.0% | -10.4% | |
| Q1 2023 | +4.4% | +0.6% | +6.9% | |
| Q4 2022 | +1.2% | +0.6% | +8.4% | |
| Q3 2022 | -3.7% | -7.4% | -7.8% | |
| Q2 2022 | +7.8% | +12.1% | +26.8% | |
| Q1 2022 | -1.8% | -9.3% | -18.4% | |
| Q4 2021 | -8.3% | -13.7% | +0.8% | |
| Q3 2021 | +3.6% | +6.2% | +4.0% | |
| Q2 2021 | +8.6% | +4.3% | +11.1% | |
| Q1 2021 | +8.9% | +26.7% | -0.1% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro